These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 33413190)

  • 1. Risk factors of recurrent erysipelas in adult Chinese patients: a prospective cohort study.
    Li A; Wang N; Ge L; Xin H; Li W
    BMC Infect Dis; 2021 Jan; 21(1):26. PubMed ID: 33413190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recurrent erysipelas: risk factors.
    Pavlotsky F; Amrani S; Trau H
    J Dtsch Dermatol Ges; 2004 Feb; 2(2):89-95. PubMed ID: 16279242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erysipelas as a sign of subclinical primary lymphoedema: a prospective quantitative scintigraphic study of 40 patients with unilateral erysipelas of the leg.
    Damstra RJ; van Steensel MA; Boomsma JH; Nelemans P; Veraart JC
    Br J Dermatol; 2008 Jun; 158(6):1210-5. PubMed ID: 18363756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent erysipelas: predisposing factors and costs of prophylaxis.
    Jorup-Rönström C; Britton S
    Infection; 1987; 15(2):105-6. PubMed ID: 3110071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with acute and recurrent erysipelas in a young population: a retrospective of 147 cases.
    Chamli A; Jaber K; Ben Lagha I; Ben Slimane M; Rabhi F; Doss N; Dhaoui MR
    Tunis Med; 2021 Aout; 99(8):886-889. PubMed ID: 35261016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erysipelas of the upper extremity following locoregional therapy for breast cancer.
    El Saghir NS; Otrock ZK; Bizri AR; Uwaydah MM; Oghlakian GO
    Breast; 2005 Oct; 14(5):347-51. PubMed ID: 15990307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erysipelas of the leg: A cross-sectional study of risk factors for recurrence.
    Hali F; Belanouane S; Zarouali Ouariti K; Sodqi M; Chiheb S
    Ann Dermatol Venereol; 2022 Jun; 149(2):119-122. PubMed ID: 34742579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent erysipelas--risk factors and clinical presentation.
    Inghammar M; Rasmussen M; Linder A
    BMC Infect Dis; 2014 May; 14():270. PubMed ID: 24884840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The erysipelas as complication of a lymph oedema after therapy of mastocarcinomas (author's transl)].
    Keinert K; Schalldach U; Schumann E
    Strahlentherapie; 1981 Feb; 157(2):91-3. PubMed ID: 7222137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recurrent erysipelas].
    Dangoisse C; Ledoux M
    Rev Med Brux; 1991 Sep; 12(7):253-6. PubMed ID: 1925175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzathine penicillin G once-every-3-week prophylaxis for recurrent erysipelas a retrospective study of 132 patients.
    Rob F; Hercogová J
    J Dermatolog Treat; 2018 Feb; 29(1):39-43. PubMed ID: 28489486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence of lymphoedema-associated cellulitis (erysipelas) under prophylactic antibiotherapy: a retrospective cohort study.
    Vignes S; Dupuy A
    J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):818-22. PubMed ID: 16898904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of reduction operation with genital lymphedema on the frequency of erysipelas and the quality of life.
    Zvonik M; Földi E; Felmerer G
    Lymphology; 2011 Sep; 44(3):121-30. PubMed ID: 22165582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recurrent erysipelas and bilateral congenital lymphedema].
    Ruiz Villaverde R; Martínez Larios B; Páramo Rodríguez E; Blasco Melguizo J; Martín Sánchez MC
    Rev Clin Esp; 2003 Aug; 203(8):403-5. PubMed ID: 12855125
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidemiological data and comorbidities of 428 patients hospitalized with erysipelas.
    Pereira de Godoy JM; Galacini Massari P; Yoshino Rosinha M; Marinelli Brandão R; Foroni Casas AL
    Angiology; 2010 Jul; 61(5):492-4. PubMed ID: 20147345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In Search of Risk Factors for Recurrent Erysipelas and Cellulitis of the Lower Limb: A Cross-Sectional Study of Epidemiological Characteristics of Patients Hospitalized due to Skin and Soft-Tissue Infections.
    Sapuła M; Krankowska D; Wiercińska-Drapało A
    Interdiscip Perspect Infect Dis; 2020; 2020():1307232. PubMed ID: 32454817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent erysipelas caused by group B streptococcus organisms.
    Binnick AN; Klein RB; Baughman RD
    Arch Dermatol; 1980 Jul; 116(7):798-9. PubMed ID: 6772113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors associated with a reduced response in the treatment of erysipelas.
    Linke M; Booken N
    J Dtsch Dermatol Ges; 2015 Mar; 13(3):217-25. PubMed ID: 25706926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium selenite as prophylaxis against erysipelas in secondary lymphedema.
    Kasseroller R
    Anticancer Res; 1998; 18(3C):2227-30. PubMed ID: 9703790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Erysipelas and lymphedema--egg or hen?].
    Stöberl C; Partsch H
    Z Hautkr; 1987 Jan; 62(1):56-62. PubMed ID: 3577282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.